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Cellular protein homeostasis (proteostasis) maintains the integrity of the proteome and includes protein synthesis, folding, oligomer-
ization, and turnover; chaperone proteins assist with all of these processes. Neurons appear to be especially susceptible to failures in
proteostasis, and this is now increasingly recognized as a major origin of neurodegenerative disease. This review, based on a mini-
symposium presented at the 2015 Society for Neuroscience meeting, describes new work in the area of neuronal proteostasis, with a
specific focus on the roles and therapeutic uses of protein chaperones.We first present a brief review of proteinmisfolding and aggrega-
tion in neurodegenerative disease. We then discuss different aspects of chaperone control of neuronal proteostasis on topics ranging
from chaperone engineering, to chaperone-mediated blockade of protein oligomerization and cytotoxicity, to the potential rescue of
neurodegenerative processes using modified chaperone proteins.
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Introduction
Proteostasis is a collection of cellular processes, including protein
synthesis, folding, oligomerization, and turnover, that functions
to ensure the integrity of the proteome. For unknown reasons,
neurons appear to be particularly susceptible to genetic and en-
vironmental insults to proteostasis, and aberrant proteostasis is
now acknowledged as a major underlying cause of neurodegen-
erative disease (for review, see Doyle et al., 2013; Hetz and
Mollereau, 2014; Valastyan and Lindquist, 2014). Protein mis-
folding and aggregation can induce specific neurotoxic events
that underlie a number of lethal and presently untreatable neu-
rodegenerative diseases. Aggregation-susceptible proteins in-
clude, but are not limited to, tau and -amyloid in Alzheimer’s
disease; -synuclein (-syn) in Parkinson’s disease; RNA-
binding proteins with prion-like domains in frontotemporal
dementia and amyotrophic lateral sclerosis; polyglutamine-
containing proteins inHuntington’s disease and spinal cerebellar
ataxias; and prion proteins in Creuzfeldt-Jakob disease. There
have been recent relevant reviews (Eisenberg and Jucker, 2012;
Ling et al., 2013; Knowles et al., 2014).
Misfolded and aggregated proteins present a significant cellu-
lar burden that must be dealt with. Protein chaperones can pre-
vent the aggregation of unfolded polypeptide chains (Hartl et al.,
2011; Kim et al., 2013), promote their de novo folding or refolding
(Hartl et al., 2011; Kim et al., 2013), cooperate with proteases to
facilitate protein degradation (Pickart and Cohen, 2004; Alexo-
poulos et al., 2012; Li and Lucius, 2013), and disaggregate protein
aggregates (Weibezahn et al., 2005; Hodson et al., 2012; Winkler
et al., 2012). Increasing evidence implicates chaperone proteins
in the etiology of neurodegenerative disease involving aggrega-
tive processes. Neuroprotection studies show thatmany different
chaperone proteins are neuroprotective in variousmousemodels
of neurodegeneration (for recent reviews, see Wyatt et al., 2012;
Carman et al., 2013; Witt, 2013).
In the following summary of our mini-symposium, different
aspects of chaperone action in neurodegenerative processes are
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Significance Statement
Aberrant protein homeostasis within neurons results in protein misfolding and aggregation. In this review, we discuss specific
roles for protein chaperones in the oligomerization, assembly, and disaggregation of proteins known to be abnormally folded in
neurodegenerative disease. Collectively, our goal is to identify therapeuticmechanisms to reduce the cellular toxicity of abnormal
aggregates.
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discussed, from the regulation of extracellular proteostasis to the
design of therapeutic molecules.
Protein disaggregases to counter neurodegeneration
There are still no effective therapeutics that directly target and
remediate the protein-misfolding events and selective neuronal
vulnerability that underpin the many devastating neurodegen-
erative disorders. Therapeutic agents that reverse deleterious
protein misfolding and aggregation in a manner that restores
previously misfolded proteins to native form and function could
be highly beneficial as they would simultaneously eliminate any
deleterious loss of function or toxic gain of function caused by
misfolded conformers (Jackrel and Shorter, 2015). Moreover,
this type of disruptive technology would also eradicate any aber-
rant self-templating or prion-like conformers that spread disease
pathology and drive the biogenesis of toxic, soluble oligomers
(Knowles et al., 2014; Jackrel and Shorter, 2015).
Efficacious therapeutic agents have been constructed by
protein engineering of the heat shock protein Hsp104, a protein
disaggregase and ATPase associated with diverse activities
(AAA) protein from yeast (Jackrel and Shorter, 2015). In yeast,
Hsp104 collaborates with the other heat shock proteins Hsp110,
Hsp70, Hsp40, and small heat shock proteins to effectively disag-
gregate and reactivate proteins trapped in disordered aggregates
after environmental stresses, such as heat shock (Glover and
Lindquist, 1998; Cashikar et al., 2005; Shorter, 2011; Torrente
and Shorter, 2013). Moreover, Hsp104 can also dissolve diverse
amyloid conformers and eliminate toxic, soluble preamyloid oli-
gomers (Shorter and Lindquist, 2004; Lo Bianco et al., 2008; De-
Santis et al., 2012). However, Hsp104 activity against human
neurodegenerative disease proteins is often limited and requires
very high levels of Hsp104 (DeSantis et al., 2012). Thus, the
Hsp104 sequence must be modified to effectively disaggregate
misfolded proteins tightly linkedwith Parkinson’s disease, amyo-
trophic lateral sclerosis, and frontotemporal dementia (Jackrel
and Shorter, 2015).
Remarkably, very subtlemodifications of theHsp104 primary
sequence (e.g., a single Ala to Gly or Val to Leu substitution) can
yield large gains in protective activity against deleteriousmisfold-
ing of -syn, the aggregated protein in Parkinson’s disease (Jack-
rel and Shorter, 2014; Jackrel et al., 2014). These potentiated
Hsp104 variants also reverse the misfolding and toxicity of pro-
teins connected with ALS and FTD, including several RNA-
binding proteins with prion-like domains: TDP-43, FUS, and
TAF15 (Jackrel and Shorter, 2014; Jackrel et al., 2014).Unusually,
inmany cases, loss of amino acid identity at select positions in the
autoinhibitory coiled-coil middle domain ofHsp104, rather than
specificmutation, empowers a dramatic therapeutic gain of func-
tion (Jackrel and Shorter, 2014; Jackrel et al., 2014). Typically,
potentiating mutations in Hsp104 enhance ATPase activity, re-
duce dependence on the Hsp70 chaperone system, and enhance
protein translocase and remodeling activity (Jackrel and Shorter,
2014; Jackrel et al., 2014). Importantly, potentiated Hsp104 vari-
ants also provide neuroprotection in the context of themetazoan
nervous system and prevent dopaminergic neurodegeneration
caused by -syn in Caenorhabditis elegans (Jackrel et al., 2014).
Potentiated Hsp104 variants may also be used against other
proteins that misfold in neurodegenerative disease, including the
-amyloid polypeptide-derived peptide A, tau, and SOD1
(Cushman et al., 2010). However, some human neurodegenera-
tive disease proteins are more refractory to potentiated Hsp104
variants. For example, the misfolding and toxicity of EWSR1, an
RNA-binding protein with a prion-like domain linked to
amyotrophic lateral sclerosis and frontotemporal dementia
(Couthouis et al., 2012; King et al., 2012), could not be buffered
by potentiated Hsp104 variants (Jackrel and Shorter, 2014). This
finding suggests that further amelioration of Hsp104 disaggre-
gase activity or alteration of substrate specificity may be neces-
sary. Laboratory evolution of alternative potentiated Hsp104
variants can potentially generate selectivity for individual human
disease substrates tomaximize therapeutic efficacy andminimize
any potential toxic, off-target effects. Collectively, these studies
suggest that general neuroprotection could be achievable for sev-
eral diverse neurodegenerative conditions via remarkably subtle
structural modifications of existing molecular chaperones or
protein disaggregases (Jackrel and Shorter, 2015).
Regulation of extracellular proteostasis through the
unfolded protein response
Extracellular protein aggregation is also intricately associated
with the onset and pathogenesis of etiologically diverse amyloid
diseases, including the systemic amyloidoses and neurodegenera-
tive disorders, such as Alzheimer’s disease and Creutzfeldt-Jakob
disease (Blancas-Mejía and Ramirez-Alvarado, 2013; Knowles et
al., 2014). In these disorders, specific misfolding-prone proteins
fail to maintain a folded conformation in the extracellular space,
which facilitates their aggregation into proteotoxic soluble oli-
gomers and amyloid fibrils. All of the proteins associated with
amyloid disease pathology are targeted to the endoplasmic retic-
ulum (ER) where they interact with ER protein homeostasis (or
proteostasis) factors, such as chaperones to attain a folded con-
formation. Once folded, these proteins are trafficked to the ex-
tracellular space through the canonical secretory pathway.
Imbalances in ER proteostasis induced by ER stress can increase
the secretion of misfolded conformations of amyloidogenic pro-
teins and promote the extracellular proteotoxic aggregation
involved in amyloid disease pathology. As such, ER stress is asso-
ciated with the onset and pathology of many human amyloid
diseases (Ryno et al., 2013; Hetz and Mollereau, 2014).
The predominant stress-responsive signaling pathway re-
sponsible for regulating ER proteostasis is the unfolded protein
response (UPR) (Walter and Ron, 2011). The UPR is activated in
response to pathologic insults that induce ER stress. Activation of
the UPR restores ER proteostasis primarily through the tran-
scriptional remodeling of ER protein folding, trafficking, and
degradation pathways. Activation of UPR signaling pathways en-
hances ER quality control and attenuates secretion and sub-
sequent extracellular proteotoxic aggregation of destabilized,
misfolding-prone proteins associated with amyloid disease pa-
thology (Shoulders et al., 2013; Cooley et al., 2014; Genereux et
al., 2015). Despite the importance of UPR signaling in preventing
the secretion of destabilized, amyloidogenic proteins, the in-
volvement of the UPR in regulating extracellular proteostasis
pathways, composed of ATP-independent secreted chaperones
(e.g., clusterin) (Wyatt et al., 2013), is poorly understood. Fur-
thermore, the specific mechanisms by which UPR signaling co-
ordinates ER and extracellular proteostasis pathway composition
and activity are largely unknown. Because ER stress has the po-
tential to influence the secretion and subsequent proteotoxic ag-
gregation of amyloidogenic proteins, it is important to evaluate
howUPR activation regulates extracellular proteostasis following
pathologic ER insults.
A bioinformatics approach was used to identify ERdj3/
DNAJB11 as a UPR-regulated secreted chaperone that promotes
extracellular proteostasis during conditions of ER stress (Ge-
nereux et al., 2015). ER stress and stress-independent activation
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of UPR-associated transcription factors induce ERdj3 secretion
to the extracellular space. Secreted ERdj3 binds tomisfolded pro-
teins and attenuates proteotoxic misfolding and/or aggregation
of amyloidogenic proteins, including the A peptide and toxic
prion protein conformations involved in Alzheimer’s disease
and Creutzfeldt-Jakob disease, respectively. Moreover, ERdj3 is
cosecreted with destabilized, amyloidogenic proteins during
conditions when ER proteostasis pathways are overwhelmed,
preemptively protecting the extracellular environment from
misfolding-prone proteins that can be secreted during conditions
of ER stress. Ultimately, these results identify UPR-dependent
increases in ERdj3 secretion as a previously unanticipated mech-
anism by which the UPR directly regulates extracellular proteos-
tasis capacity during conditions of ER stress. Furthermore, ERdj3
cosecretion with misfolded protein conformations provides a
mechanism to coordinate intracellular and extracellular proteo-
stasis environments in response to pathologic insult. The identi-
fication of ERdj3 as a UPR-regulated extracellular chaperone
provides a new framework to define the specific contributions of
ER stress and UPR signaling in the pathophysiology of amyloid
diseases and reveals ERdj3 secretion as a new potential therapeu-
tic target to intervene in these disorders.
Chaperones can bind to and suppress the toxicity of
preformed protein oligomers
As discussed above, protein chaperones act to promote folding,
block aggregation, disaggregate proteins, and facilitate protein
degradation. In addition to these well-established functions, mo-
lecular chaperones have also recently been found to suppress the
cytotoxic effects of protein aggregates after these are formed
(Ojha et al., 2011; Binger et al., 2013; Cascella et al., 2013; Man-
nini et al., 2014).
Early studies showed that in vitro incubation of preformed
oligomers of the A peptide with a fivefold lower concentration
ofHsp27 (also known asHSPB1) inhibited the oligomer-induced
loss of cell viability (Ojha et al., 2011). Biochemical and biophys-
ical methods based on atomic force microscopy, transmission
electron microscopy, confocal microscopy coupled to immuno-
staining, light scattering, and centrifugation assays, in conjunc-
tion with SDS-PAGE, showed that Hsp27 inhibited A oligomer
toxicity by binding to oligomeric species and converting them
into larger aggregates. Interestingly, thioflavin T fluorescence,
8-anilinonaphthalene-1-sulfonic acid fluorescence, and far-UV
circular dichroism spectroscopy provided no evidence for any
significant structural change in the preformed oligomers follow-
ing incubation with Hsp27, indicating that the A structural
modification by chaperone involved only quaternary, not sec-
ondary or tertiary, structure.
Other chaperones can also suppress the toxicity of misfolded
proteins. When preformed misfolded oligomers of A, islet am-
yloid polypeptide, or the model prokaryotic protein HypF-N
were incubated in vitrowith substoichiometric concentrations of
the chaperones B-crystallin (HSPB5), Hsp70 (HSPA1A), clus-
terin, 2-macroglobulin, or haptoglobin, they were converted
into large nontoxic aggregates, as determined using SDS-PAGE,
fluorescence, confocal microscopy coupled to immunofluores-
cence, and atomic force microscopy (Mannini et al., 2014).
Again, conversion of the small oligomers into large aggregates
occurred in the absence of any significant structural reorganiza-
tion of the individual molecules within the aggregates, as deter-
mined with Fourier-transform infrared spectroscopy and pyrene
labeling. Thus, chaperones can promote further assembly of po-
tentially toxic oligomeric species into larger species.
In addition to the chaperones cited above, human tetrameric
transthyretin (hTTR) and its engineered monomeric variant
(M-TTR) have also been used to suppress the aggregation of
aberrant protein oligomers (Li et al., 2011; Cascella et al., 2013; Li
et al., 2013). Although the serum protein hTTR is not generally
classified as a chaperone, it had previously been found to prevent
the aggregation of A, acting in a chaperone-like manner
(Schwarzman et al., 1994; Choi et al., 2007; Buxbaum et al.,
2008). Both TTRs, particularly M-TTR, effectively inhibited the
toxicity of A and HypF-N oligomers in vitro. When acting on
preformedHypF-N oligomers, themechanism of action for their
biological neutralization was again found to consist of a TTR-
induced clustering of the oligomers to produce larger species
(Cascella et al., 2013).
Non-neuronal misfolded proteins can also represent sub-
strates for chaperone-mediated structural reorganization. For ex-
ample, the amyloid fibrils formed by apolipoprotein C-II were
converted into large fibrillar tangles in the presence of B-
crystallin (Binger et al., 2013). Although the ability of the indi-
vidual and assembled fibrils to cause cell dysfunction was not
directly tested in this case, the clustered fibrils lost their ability to
dissociate into small oligomers and promote secondary nucle-
ation, providing indirect evidence of their diminished toxicity
(Binger et al., 2013).
In sum, the ability of protein chaperones to biologically neu-
tralize preformed toxic aggregates is a relatively novel and previ-
ously unappreciated function, and is worth further exploration in
vitro, in cultured cells and animal models, and in aging and path-
ological states.
The neuronal secretory chaperones 7B2 and
proSAAS suppress the aggregation of
neurodegenerative disease-related proteins
While all cells express the heat shock and common secretory
chaperones discussed above, few chaperone proteins have
been identified thus far that are specific to neurons. The lack of
neural-specific chaperones is somewhat surprising, considering a
presumably intense requirement for chaperone action within the
synaptic cleft. Recently, two neural- and endocrine-specific se-
cretory proteins, proSAAS and 7B2, were shown to exhibit dis-
tinct anti-aggregant chaperone activities. The 7B2 protein,
originally identified as a neuroendocrine marker protein (Iguchi
et al., 1984), exerts a potent anti-aggregant effect on the
neuropeptide-synthesizing enzyme precursor, prohormone con-
vertase 2 (proPC2); indeed, in the absence of 7B2, proPC2 un-
dergoes inactivating aggregation (Lee and Lindberg, 2008). The
anti-aggregant action of 7B2 on recombinant IGF1 produced in
yeast had indeed been noted over a decade previously (Chaud-
huri et al., 1995). ProSAAS was initially discovered through a
peptidomics screen of abundant brain neuropeptides (Fricker et
al., 2000); like 7B2, proSAAS is widely distributed within neuro-
nal and endocrine tissues (Lanoue and Day, 2001; Feng et al.,
2002). Whereas 7B2 is expressed both in vertebrates and inverte-
brates (for review, see Mbikay et al., 2001), proSAAS is found
only in vertebrates, and residue conservation in lower vertebrates
occurs only within a central core domain (Kudo et al., 2009). In
agreement, mouse proSAAS undergoes limited processing at the
amino and carboxy termini to several potentially bioactive pep-
tides, but an 100-residue core of proSAAS remains intact
(Sayah et al., 2001; Mzhavia et al., 2002). No significant homol-
ogy with other proteins, including known chaperones, is present
within this core domain, nor are 7B2 or proSAAS homologous
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with each other, despite certain structural similarities. Recombi-
nant 7B2, an intrinsically disordered protein, spontaneously oli-
gomerizes (Dasgupta et al., 2012) and is more soluble in the cold
than at room temperature, a peculiar property reminiscent of
certain small Hsps (for review, see Hilton et al., 2013). Little is
known as to the tertiary or quaternary structure of proSAAS,
largely due to the insolubility of the recombinant protein.
Both recombinant 7B2 as well as recombinant proSAAS dose-
dependently block the aggregation of A into thioflavin-T bind-
ing fibrils as well as A-induced cytotoxicity (Helwig et al., 2013;
Hoshino et al., 2014). Inhibition is ATP-independent and sub-
stoichiometric (Helwig et al., 2013; Hoshino et al., 2014). For
both proteins, anti-aggregation action appears to approximately
localize to the core sequence discussed above (Helwig et al., 2013;
Hoshino et al., 2014; T. Jarvela and I. Lindberg, unpublished
results). Recent work shows that proSAAS also functions as a
potent anti-aggregant for -syn (T. Jarvela and I. Lindberg, un-
published results). Indeed, proSAAS immunoreactivity colocal-
izes with Lewy bodies in nigral slices from a Parkinson’s patient
(M. Helwig and I. Lindberg, unpublished results), supporting
results of earlier studies demonstrating that proSAAS colocalizes
with inclusion bodies in neurodegenerative disease (Kikuchi et
al., 2003; Wada et al., 2004).
Additional support for the idea that proSAAS could be in-
volved in neurodegenerative processes is supplied by the fact that
five independent proteomics studies have identified proSAAS as a
potential CSF biomarker in various neurodegenerative diseases
(Davidsson et al., 2002; Abdi et al., 2006; Finehout et al., 2007;
Jahn et al., 2011; Choi et al., 2013), with four proteomics studies
finding alterations in 7B2 levels (Pasinetti et al., 2006; Finehout et
al., 2007; Baye´s and Grant, 2009; Jahn et al., 2011). Collectively,
these studies support the idea that neuronal 7B2 and proSAAS
not only represent potential therapeutic targets for controlling
protein aggregation in neurodegenerative disease, but may also
constitute useful biomarkers.
Controlling tau aggregation and toxicity with Hsp90
chaperone complexes
Themicrotubule-associatedprotein tau accumulates in anumber of
neurodegenerative diseases termed tauopathies, leading to forma-
tion of neurofibrillary tangles, neuronal loss, and cognitive deficits.
This pathogenic cascade can be caused by mutations in theMAPT
gene itself that codes for tau protein and by post-translationalmod-
ifications, includingphosphorylationandacetylation (Goedert et al.,
1988; Hutton et al., 1998; Spillantini et al., 1998; Zhou et al., 2000;
von Bergen et al., 2001; Mueller et al., 2006; Ma et al., 2012a, b).
Interestingly, another post-translational modification to tau, ubiq-
uitination,hasbeenshowntoberequired for tau-sheet assembly in
vivo. However, whenubiquitination is blocked, soluble tau interme-
diates arise in thebrain that arehighly toxic (Dickey et al., 2006).The
idea that soluble tau intermediates represent themajor toxic species
in the brain has gained recent support from key studies that have
emerged over the past decade (Santacruz et al., 2005; Oddo et al.,
2006; O’Leary et al., 2010; Thuringer et al., 2013). More recently,
using tools that have beendeveloped to specifically investigate oligo-
meric tau species, it has been proven that oligomeric tau is respon-
sible for much of the neurotoxicity due to tau accumulation (Hall
andPatuto, 2012; Blair et al., 2013). It is clear that understanding the
processes governing tau oligomerization and aggregation is critical
not only for controlling tau pathogenesis but also for developing
tau-based therapeutics.
Although recent evidence suggests that intermediate oligomers
of tau are more neurotoxic in tauopathies than densely packed
-sheet fibrils, this has remained unproven because relevant mech-
anisms to trap distinct assemblies of tau aggregates have been lack-
ing. The Hsp90/cochaperone machinery can be used to control tau
structure and assembly to investigate how tau aggregate structure
relates to its toxicity.Tauphysically interactswithHsp90, and indeed
provided the first 3D structure of a client complexed with Hsp90
(Karago¨z et al., 2014). Whereas Hsp90 levels are largely static in the
aging brain, a group of cochaperones that can interface with tau
through Hsp90 is much more dynamic; some rise and others fall
during a lifetime. Interestingly, Hsp90 and a recently identified co-
chaperone, the cis-/trans peptidyl-prolyl isomerase (PPIase) FK506
binding protein 51 (FKBP51), coordinate to provoke tau pathogen-
esis by reducing tau -sheet amyloidosis (Blair et al., 2013). This
corresponds with increased oligomerization and neurotoxicity in
tau transgenicmice. Thus, theHsp90 complexmay control whether
tau aggregates into toxic or benign species, depending on the associ-
ated cochaperones.
Just as FKBP51 levels increase in the aging brain, so do the levels
of a second Hsp90-associated cochaperone and to an even greater
extent than FKBP51 (C. A. Dickey et al., unpublished results). Like
FKBP51, this second cochaperone protein reduces tau aggregation
and produces amorphous intermediates. Two other cochaperones
enhance the -sheet propensity of tau (C. A. Dickey et al., unpub-
lished results). These new proteostatic tools have permitted the in-
terrogation of the role of tau aggregation in neurotoxicity. These
studies suggest that itmaybepossible to identifyways to regulate tau
aggregation using the dynamic Hsp90 complex, which then guides
the identification of toxic tau intermediate structures. Preliminary
results indicate that distinctHsp90/co chaperone complexes candif-
ferentially triage aberrant tau, illuminating heteromeric complexes
that could be targeted for therapeutic development. Increasing evi-
dence indicates that the triage of normal tauwithin the cell is largely
dependent on the associated chaperone complement, and that these
chaperone complexes govern tau triage tomicrotubules, lysosomes,
and even exosomes. Insight into the control of cellular triage deci-
sions is critical for our understanding of tau biology and its role in
neurodegenerative disease.
Hsp90 inhibitors as potential therapeutics for
Parkinson’s disease and related synucleinopathies
Hsps colocalize with misfolded and aggregated proteins in multiple
neurodegenerative disorders, including Parkinson’s disease (PD)
(Jones et al., 2014). One of themost widely studiedmolecular chap-
erone Hsps with respect to neurodegenerative disorders is Hsp70,
which can direct misfolded and potentially toxic proteins for degra-
dation via the proteasome or autophagy-lysosomal pathways
(Petrucelli et al., 2004; Kon and Cuervo, 2010; Ebrahimi-Fakhari et
al., 2011). Induction of Hsp70 is protective in models of Hunting-
ton’s disease, spinocerebellar ataxias, and tauopathy disorders (i.e.,
Alzheimer’s disease) (Fujikake et al., 2008; Deture et al., 2010). Sev-
eral groups have demonstrated that Hsp70 upregulation enhances
degradation ofmisfolded-syn, reduces-syn oligomer formation,
and reduces toxicity inducedby-synoverexpression (Auluck et al.,
2002;McLean et al., 2002, 2004; Klucken et al., 2006). Indeed, cross-
ing mice overexpressing Hsp70 with -syn transgenic mice reduces
insoluble, highmolecularweight-syn species,whichare also found
in the brains of patients with Lewy body-associated dementia, but
not healthy controls (Klucken et al., 2006). Moreover, direct phar-
macological upregulation of Hsp70 with various Hsp90 inhibitors
decreases -syn-induced cytotoxicity and aggregation (McLean et
al., 2004; Putcha et al., 2010). Thus, targetingmolecular chaperones,
such asHsp70 orHsp90, is therapeutically relevant not only for PD,
but also for related neurodegenerative disorders.
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BecauseHSPs have emerged as potentially therapeuticmodifiers
of cytotoxicity in PD, mounting data suggest that upregulating
Hsp70, either directly by overexpression or indirectly via inhibition
of Hsp90, could be a favorable therapeutic approach. Indeed, treat-
mentwithnovel,brain-permeableHsp90 inhibitors increasesHsp70
levels and reduces -syn-induced aggregation and toxicity in cell
models (Putcha et al., 2010). In rats, the same compounds dramati-
cally induce Hsp70 expression in rat brain, prevent -syn oligomer
formation in vivo, and restore lost dopamine levels in the striatum
(McFarlandet al., 2014).Unfortunately, amajor limitationofHsp90
inhibitor therapy is the associated widespread toxicity, which has
been reported for almost all Hsp90 inhibitors tested in vivo to date.
Because Hsp90 inhibitor therapy may prove an unreasonable
therapeutic approach, other related pathways have been investi-
gated. In support of a therapeutic role for Hsp70 upregulation for
PD, the cochaperone carboxyl terminus of Hsp70-interacting pro-
tein (CHIP) colocalizes with -syn and Hsp70 in LBs in human
brain (Shin et al., 2005) andmediates ubiquitination of-syn (Kalia
et al., 2011). CHIP can mediate -syn degradation via two discrete
mechanisms: the proteasomal degradation pathway and the lyso-
somal degradation pathway. CHIP overexpression inhibits -syn
inclusion formation and also reduces -syn protein levels in cell
models (Shin et al., 2005). Furthermore, using a novel bimolecular
complementation assay, CHIP was shown to selectively target toxic
-syn oligomers for degradation (Tetzlaff et al., 2008). As such,
modulating CHIP levels may represent an additional therapeutic
strategy for PD.
In addition to inducing a heat shock response and upregulating
Hsp70, inhibition ofHsp90may also prevent the release of extracel-
lular -syn and thus prevent or slow the propagation of -syn pa-
thologyanddiseaseprogression.Extracellular-syn is resecretedout
of neurons by a regulator of the recycling endosome Rab11a (Liu et
al., 2009), and Hsp90 interacts with Rab11a during this process.
Hsp90 inhibition prevents the resecretion of extracellular-syn and
attenuates the associated toxicity. The rapidly evolving field of PD
propagation has resulted in a plethora of studies on extracellular
-syn. Of interest, upregulation of Hsp70 reduces extracellular oli-
gomers by a striking 84% and rescues associated toxicity in cell cul-
ture models (Danzer et al., 2011).
In sum, targeting the cytoplasmic chaperoneHsp90, and thereby
augmenting the cellular response to stressors, may represent a rea-
sonable therapeutic approach for neurodegenerative diseases but
still requires further investigation and drug discovery efforts.
In conclusion, it is now clear that disease- and aging-associated
defects in neuronal proteostasis underlie many of the cellularmani-
festations of neurodegenerative disease, and the various roles of
chaperone proteins in controlling the formation, disposition, and
cytotoxicity of aberrant protein aggregates are accordingly receiving
increasing attention. These brief summaries of currentwork present
diverse approaches to the study of chaperone proteins in neurode-
generation. The different cellular locations of chaperone action pro-
vide a variety of possibilities for chaperone use in therapeutic
intervention, from controlling the initial aggregative events in the
ER, toblocking the assemblyof cytotoxic aggregates, to reversing the
formation of extracellular toxic oligomers.
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